NOT FOR DISTRIBUTION IN THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN

Reference is made to the announcement made by NorDiag ASA (the "Company") on 9 December 2011 regarding the rights issue and the conversion issue.
 
The share capital increase related to the rights issue in the Company resolved by the Company's General Meeting on 2 November 2011 has now been registered with the Norwegian Register of Business Enterprises and, hence, the rights issue has been completed.
 
The part of the conversion issue relating to the set-off against the underwriting fee resolved in the same General Meeting on 2 November 2011 has also been registered with the Norwegian Register of Business Enterprises and this part of the conversion issue is thus also completed.
 
The new share capital of the Company is NOK 5,419,532.22 divided into 270,976,611 shares, each with a nominal value of NOK 0.02.
 
The new shares are delivered to subscribers registered in the VPS today and are tradable on Oslo Børs.
 
The share capital increase relating to the part of the conversion issue which relates to the set-off against interest on the bridge loan is expected to be registered with the Norwegian Register of Business Enterprises on or about 22 December 2011.
 
For further information, please contact:
CEO Mårten Wigstøl, Phone: +47 911 65775
CFO Tone Kvåle,  Phone: +47 915 19576
 
About NorDiag:
NorDiag ASA is a biotechnology company developing, manufacturing and marketing automated solutions (instruments and kits) for isolation of nucleic acids and cells (sample preparation) from biological samples, making the samples ready for downstream analysis. The Company aims to be a leading provider of automated sample preparation systems, with focus on isolation of nucleic acids and cells from difficult samples. NorDiag's fully automated instruments, Arrow and Bullet, can be used for a broad range of applications and protocols. The instruments meet the needs of both the clinical diagnostic market and the life science markets. NorDiag was founded in 2003 and has its headquarters in Oslo, Norway. The Company has offices and laboratories in Stockholm, Sweden and Atlanta (GA), USA. NorDiag is listed on the Oslo Stock Exchange with ticker NORD. The group has today 31.6 man-labour years. NorDiag is listed on the Oslo Stock Exchange with ticker NORD.
 
 For further information - www.nordiag.com.

Read the notice in Norwegian here.